.After increasing $170 thousand back in February, metabolic disease-focused BioAge Labs has actually submitted to debut on the general public market.The Eli Lilly-partnered biotech hopes to detail on the Nasdaq under the sign "BIOA," depending on to documentations filed with the Securities and also Substitution Commission. The provider has not openly shared an assumed monetary volume for the offering.The clinical-stage company boasts lead applicant azelaprag, a by mouth provided small molecule slated to get into phase 2 testing in combo along with semaglutide-- marketed by Novo Nordisk under brand name Wegovy for weight management-- in the very first half of upcoming year. Semaglutide is likewise sold as Ozempic and also Rybelsus through Novo for diabetic issues.
Apelin receptor agonist azelaprag is actually developed to integrate properly with GLP-1 drugs, improving weight reduction while keeping muscle mass. The investigational medication was actually discovered to become well-tolerated among 265 individuals across 8 stage 1 trials, according to BioAge.Previously, BioAge garnered the help of Lilly to operate a trial mixing azelaprag along with the Large Pharma's GLP-1/ GIP receptor agonist tirzepatide, which is actually industried for diabetes mellitus as Mounjaro and also Zepbound for fat loss. The partners are actually currently performing a phase 2 trial of azelaprag as well as tirzepatide, with topline outcomes assumed in the 3rd quarter of 2025.The biotech is also intending a blood insulin sensitivity proof-of-concept test assessing azelaprag as a monotherapy in the first half of following year to assist potential indication development. On top of that, the firm intends to talk to the FDA for consent in the second one-half of 2025 to introduce individual testing for an NLRP3 prevention targeting metabolic diseases and neuroinflammation.BioAge's foreseed transfer to everyone market follows a slight uptick in considered biotech IPOs from Bicara Therapies and Zenas Biopharma. Zooming out, the latest IPO yard is a "combined photo," with top quality firms still debuting on the general public markets, only in lowered numbers, depending on to PitchBook.